From insiderwire.com
posted on Yahoo
Current Pick: Immune Response Corporation
IMNR : NASDAQ (Picked at $13.69 to perform on 6/12/98 )
IMMUNE RESPONSE CORP (NASDAQ:IMNR)
Bid
13.56
Ask
13.69
Bid x Ask
9x10
Volume
1,034,200
Last Price (Time)
13.69 (06/11)
Open
12.00
High
13.75
Low
11.88
Prev Close
11.75
Change (%)
1.94 (+16.49%)
52 Week High
14.50
52 Week Low
7.31
EPS
0.00
P/E
-8.94
Shares Outstanding
22,767,000
Ex-Div Date
00/00/00
Div Frequency
not avail.
Div Amount
0.00
Yield
0.00
Volatility
40.03
Income Statement | Balance Sheet
IMNR Snapshot:
While many tech stocks have continued to see downward movement, certain bio stocks have seen a
rejuvenation. Late Thursday afternoon, Immune Response rallied trading over a million shares, up over 16% on
the day. IMNR is a biopharmaceutical company developing immune-based therapies to induce specific T cell
response for the treatment of HIV, autoimmune diseases and cancer. Shareholders waited for news throughout
the day which finally announced it signed a pact with Agouron Pharmaceuticals for final development and
commercialization of HIV treatment, REMUNE, worth up to $77 million to Immune Response over two years.
Based on our analysis of IMNR, the company has the technology that pharmaceutical marketing giants would
love to get their hands on. We feel the past stock performance of Immune Response has historically been
somewhat flat due to its inability to generate cash for future growth developments. We are only speculating,
however, this agreement between AGPH and IMNR has the potential to blossom into what we consider would
be a very beneficial merger for both parties. One has the cash and the other holds the goods. In our opinion,
the climb for IMNR is not over yet. This would only be appropriate for IMNR. A company that develops
treatment to help prolong the lives of others, gets a breath of continued hope from a "biobank" savior. Some
call it karma.
|
